Skip to main content
Signal8

AVENUE THERAPEUTICS, INC. (ATXI)

Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Avenue Therapeutics, Inc. logo

Avenue Therapeutics, Inc.

OTC:ATXIHealthcare
-8.29%$0.2800
CLOSED
Mkt Cap$923K
EV-
Float2.85M
O/S3.29M
VOL3K sh
$ Vol$798
RVOL1.01×
Inst Own-
SI<0.1%
Net Cash/Sh-
Dilution
Avenue Therapeutics, Inc. logoOTC:ATXIClosed$0.2800-8.29%
Short interest (FINRA)
0.0%
Oct 30 (18d)

Float 2.85M · Signal8 dilution snapshot · Nov 6, 2026

1
Oct 30 (18d)prev 1– 0.0%
1.00
Oct 30 (18d)prev 1.00– 0.0%
Borrow (IBKR)

The cost to borrow ATXI shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
29.4%
Nov 16 (1d)prev 1.0%▲ 28.4 pts

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

1
Jun 3 (167d)prev 1– 0.0%
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Fails to deliver3 settlement dates
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 20261 sh
Oct 15, 20261 sh
Sep 30, 20261 sh
Sep 15, 20261.3K sh
Aug 31, 202612.9K sh
Latest fails to deliver
DateShares failed
Jun 3, 20261 sh
Jun 2, 20261 sh
Apr 24, 20261 sh

A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume
Nov 16
Latest sessions
DateReported short
Nov 16, 202629.4%
Nov 13, 20261.0%
Nov 12, 202688.4%
Oct 26, 202618.2%
Oct 23, 202685.5%
45-session median 33.3%mean 41.3%range 0.0–100.0%

130 calendar days requested; 46 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.

Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for ATXI: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 1 ATXI shares were sold short (<0.01% of a 2.85M-share float, 1.00 days to cover).